Grozdena Yilmaz

2 papers in the library · 26 citations · publishing 2022-2026

Papers

Antidepressant Effect of Ketamine on Inflammation‐Mediated Cytokine Dysregulation in Adults with Treatment‐Resistant Depression: Rapid Systematic Review

Oxidative Medicine and Cellular Longevity January 1, 2022 Shiryn D. Sukhram, Grozdena Yilmaz, Jianying Gu 26 citations

Ketamine infusion may reduce depressive symptoms in treatment-resistant depression (TRD), with a quick onset of effect. Based on scores from the Montgomery-Åsberg Depression Rating Scale and Hamilton Depression Rating Scale, the overall response rate for ketamine was 56%, meaning 56% of those treated had scores decrease by at least 50%. However, the evidence for ketamine's rapid antidepressant effect remains inconsistent, and its anti-inflammatory effects on specific proinflammatory cytokines are still being clarified. The findings provide a basis for future research on improving systemic inflammatory immune disorders and mental health, suggesting ketamine may be part of a comprehensive treatment for TRD patients with elevated depression-specific inflammatory biomarkers.

DOI: 10.1155/2022/1061274 Full text Ketamine Anxiety Antidepressant Depression economics +7

Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications.

Pharmaceutics January 8, 2026 Shiryn D Sukhram, Majandra Sanchez, Ayotunde Anidugbe et al.

Depression and diabetic neuropathy often co-occur with diabetes, worsening blood sugar control and quality of life. Ketamine and its S-enantiomer, esketamine, offer rapid antidepressant and pain-relieving effects, but diabetes-related changes and other medications may alter their effectiveness and safety. A scoping review of 11 studies (including human case reports, one randomized trial, narrative reviews, and rodent studies) found short-term improvements in treatment-resistant depression and neuropathic pain, including opioid-sparing postoperative pain relief in gestational diabetes. Blood sugar effects varied, with both high and low blood sugar reported. Interactions with common diabetes drugs and liver enzymes (CYP3A4, CYP2B6) remain poorly studied. The authors call for dedicated pharmacokinetic and pharmacodynamic studies to guide individualized dosing in diabetes.

DOI: 10.3390/pharmaceutics18010081 Full text Esketamine Cyp2b6 Cyp3a4 Pk-pd +5